small molecule compound

A unique collection of xnum annotated bioactive compounds with clear targets, suitable for phenotypic screening;

A unique collection of xnum approved drugs for high throughput screening (HTS) and high content screening (HCS);

A unique collection of xnum GPCR-active agents for high throughput screening and high content screening for GPCR drug discovery, and new GPCR target identification and research;

A unique collection of xnum kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.

A unique collection of xnum anticancer drugs for high throughput screening (HTS) and high content screening (HCS);

A unique collection of xnum compounds targeting lipid metabolism, can be used for high-throughput screening (HTS) and high-content screening (HCS).

A collection of xnum small molecule compounds with validated activity for high throughput screening (HTS), high content screening (HCS), cell induction, and target identification;

A unique collection of xnum FDA approved drugs for high throughput screening (HTS) and high content screening (HCS);

A unique collection of xnum promising or approved mitochondria-targeted compounds including Idebenone, the only approved drug targeting mitochondria, for research in mitochondrial medicine;

xnum well-chosen unique AMPK-targeted small molecules;

A unique collection of xnum compounds targeting MAPK signaling for drug discovery in MAPK related diseases;

A unique collection of xnum nuclear receptor signaling targeted compounds for high throughput and high content screening;

A unique collection of xnum small molecules targeting various membrane proteins.

A unique collection of xnum approved anti-cancer drugs for high throughput screening (HTS) and high content screening (HCS);

A unique collection of xnum cancer cell differentiation inducing compounds for high throughput and high content screening;

xnum Chemotherapeutic drugs that can be used for high-throughput and high-content screening.

A unique collection of xnum compounds acting on immune-oncology therapeutic targets can be used for high throughput and high content screening;

A unique collection of xnum compounds targeting ion channels for research in ion channels-related diseases and ion channel drug discovery;

A unique collection of xnum compounds targeting endocrine system for high throughput screening (HTS) and high content screening (HCS) for new drugs;

A unique collection of xnum glutamine metabolism related compounds can be used for high throughput screening (HTS) and high content screening (HCS), and also is an effective tool for research in glutamine metabolism and cancer;

A unique collection of xnum bioactive compounds specifically targeting adrenergic receptors, effective tool for screening new drugs or new target identification;

xnum small molecule compounds with pro-oxidant or anti-oxidant activity for high-throughput and high-content screening.

Oxidative stress reflects an imbalance between the systemic manifestation of reactive oxygen species (ROS) and a biological system's ability to readily detoxify the reactive intermediates or repair the resulting damage. Disturbances in the normal redox state of cells can cause toxic effects through the production of peroxides and free radicals that damage all components of the cell, including proteins, lipids, and DNA. In humans, oxidative stress is thought to be involved in the development of atherosclerosis, heart failure, myocardial infarction, cancer, infection etc. Antioxidants are a class of compounds that counteract oxidative stress and reduce oxidative damage. The TargetMol Antioxidant Compound Library is a unique collection of xnum small molecules with inhibitory effects on oxidative stress and is a useful tool for high-throughput screening and high-content screening in the study of oxidative stress.

A unique collection of xnum compounds with defined hematopoietic toxicity for high throughput and high content drug screening;